Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current HIV Research
  4. Fast Track Articles
  5. Fast Track Article
image of The Germline Targeting Vaccine Concept: Overview and Updates from HIV Pre-Clinical and Clinical Trials

Abstract

An effective HIV-1 vaccine should elicit diverse immune responses, including broadly neutralizing antibodies (bNAbs). Such antibodies recognize regions of the viral envelope glycoprotein (Env) that are conserved among the diverse HIV-1 clades and strains. They are isolated from people living with HIV-1 to protect animals from experimental viral exposure and reduce HIV-1 acquisition in clinical settings. However, despite efforts spanning several decades, bNAbs have not been elicited through immunization. The HIV Env efficiently binds bNAbs, but not their unmutated (germline, gl) precursors. In contrast, Env readily engages the germline precursors of antibodies with no, or very narrow, cross-neutralizing activities (non-neutralizing antibodies, nnAbs). That, in part, explains why Env-based immunogens consistently elicit nnAbs, but not bNAbs. In the past decade, Env-derived proteins have been specifically designed to engage the germline precursors of diverse bNAbs. These ‘germline-targeting’ Env immunogens activate the corresponding naive B cells in vivo, but are unable to guide their proper maturation towards their broadly neutralizing forms. For this, immunizations with currently not well-defined heterologous Envs are required. Here, we discuss the development of germline-targeting Env immunogens, their in vivo evaluation, and the strategies currently under evaluation that aim to rapidly guide the maturation of germline-precursor BCRs into their broadly neutralizing forms.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X358302250206074255
2025-02-21
2025-04-21

  • From This Site

    /content/journals/chr/10.2174/011570162X358302250206074255
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sok D. Burton D.R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 2018 19 11 1179 1188 10.1038/s41590‑018‑0235‑7 30333615
    [Google Scholar]
  2. Burton D.R. Ahmed R. Barouch D.H. Butera S.T. Crotty S. Godzik A. Kaufmann D.E. McElrath M.J. Nussenzweig M.C. Pulendran B. Scanlan C.N. Schief W.R. Silvestri G. Streeck H. Walker B.D. Walker L.M. Ward A.B. Wilson I.A. Wyatt R. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012 12 4 396 407 10.1016/j.chom.2012.09.008 23084910
    [Google Scholar]
  3. Haynes B.F. Wiehe K. Borrow P. Saunders K.O. Korber B. Wagh K. McMichael A.J. Kelsoe G. Hahn B.H. Alt F. Shaw G.M. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat. Rev. Immunol. 2023 23 3 142 158 10.1038/s41577‑022‑00753‑w 35962033
    [Google Scholar]
  4. Burton D.R. Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 2016 34 1 635 659 10.1146/annurev‑immunol‑041015‑055515 27168247
    [Google Scholar]
  5. Klein F. Mouquet H. Dosenovic P. Scheid J.F. Scharf L. Nussenzweig M.C. Antibodies in HIV-1 vaccine development and therapy. Science 2013 341 6151 1199 1204 10.1126/science.1241144 24031012
    [Google Scholar]
  6. Ferrari G. Pollara J. Kozink D. Harms T. Drinker M. Freel S. Moody M.A. Alam S.M. Tomaras G.D. Ochsenbauer C. Kappes J.C. Shaw G.M. Hoxie J.A. Robinson J.E. Haynes B.F. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J. Virol. 2011 85 14 7029 7036 10.1128/JVI.00171‑11 21543485
    [Google Scholar]
  7. Lu C.L. Murakowski D.K. Bournazos S. Schoofs T. Sarkar D. Halper-Stromberg A. Horwitz J.A. Nogueira L. Golijanin J. Gazumyan A. Ravetch J.V. Caskey M. Chakraborty A.K. Nussenzweig M.C. Enhanced clearance of HIV-1–infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 2016 352 6288 1001 1004 10.1126/science.aaf1279 27199430
    [Google Scholar]
  8. Bruel T. Guivel-Benhassine F. Amraoui S. Malbec M. Richard L. Bourdic K. Donahue D.A. Lorin V. Casartelli N. Noël N. Lambotte O. Mouquet H. Schwartz O. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nat. Commun. 2016 7 1 10844 10.1038/ncomms10844 26936020
    [Google Scholar]
  9. Lofano G. Gorman M.J. Yousif A.S. Yu W.H. Fox J.M. Dugast A.S. Ackerman M.E. Suscovich T.J. Weiner J. Barouch D. Streeck H. Little S. Smith D. Richman D. Lauffenburger D. Walker B.D. Diamond M.S. Alter G. Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement. Sci. Immunol. 2018 3 26 eaat7796 10.1126/sciimmunol.aat7796 30120121
    [Google Scholar]
  10. Perez L.G. Costa M.R. Todd C.A. Haynes B.F. Montefiori D.C. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: A specific role for antibodies against the membrane-proximal external region of gp41. J. Virol. 2009 83 15 7397 7410 10.1128/JVI.00656‑09 19458010
    [Google Scholar]
  11. Doria-Rose N.A. Klein R.M. Daniels M.G. O’Dell S. Nason M. Lapedes A. Bhattacharya T. Migueles S.A. Wyatt R.T. Korber B.T. Mascola J.R. Connors M. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: Clustering analysis and association with clinical variables. J. Virol. 2010 84 3 1631 1636 10.1128/JVI.01482‑09 19923174
    [Google Scholar]
  12. Hraber P. Seaman M.S. Bailer R.T. Mascola J.R. Montefiori D.C. Korber B.T. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014 28 2 163 169 10.1097/QAD.0000000000000106 24361678
    [Google Scholar]
  13. Mikell I. Sather D.N. Kalams S.A. Altfeld M. Alter G. Stamatatos L. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 2011 7 1 e1001251 10.1371/journal.ppat.1001251 21249232
    [Google Scholar]
  14. Sather D.N. Armann J. Ching L.K. Mavrantoni A. Sellhorn G. Caldwell Z. Yu X. Wood B. Self S. Kalams S. Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 2009 83 2 757 769 10.1128/JVI.02036‑08 18987148
    [Google Scholar]
  15. Stamatatos L. Morris L. Burton D.R. Mascola J.R. Neutralizing antibodies generated during natural HIV-1 infection: Good news for an HIV-1 vaccine? Nat. Med. 2009 15 8 866 870 10.1038/nm.1949 19525964
    [Google Scholar]
  16. van Gils M.J. Euler Z. Schweighardt B. Wrin T. Schuitemaker H. Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS 2009 23 18 2405 2414 10.1097/QAD.0b013e32833243e7 19770692
    [Google Scholar]
  17. Simek M.D. Rida W. Priddy F.H. Pung P. Carrow E. Laufer D.S. Lehrman J.K. Boaz M. Tarragona-Fiol T. Miiro G. Birungi J. Pozniak A. McPhee D.A. Manigart O. Karita E. Inwoley A. Jaoko W. DeHovitz J. Bekker L.G. Pitisuttithum P. Paris R. Walker L.M. Poignard P. Wrin T. Fast P.E. Burton D.R. Koff W.C. Human immunodeficiency virus type 1 elite neutralizers: Individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 2009 83 14 7337 7348 10.1128/JVI.00110‑09 19439467
    [Google Scholar]
  18. Weaver C.T. Unanue E.R. The costimulatory function of antigen-presenting cells. Immunol. Today 1990 11 2 49 55 10.1016/0167‑5699(90)90018‑5 2185780
    [Google Scholar]
  19. Seaman M.S. Janes H. Hawkins N. Grandpre L.E. Devoy C. Giri A. Coffey R.T. Harris L. Wood B. Daniels M.G. Bhattacharya T. Lapedes A. Polonis V.R. McCutchan F.E. Gilbert P.B. Self S.G. Korber B.T. Montefiori D.C. Mascola J.R. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 2010 84 3 1439 1452 10.1128/JVI.02108‑09 19939925
    [Google Scholar]
  20. Piantadosi A. Panteleeff D. Blish C.A. Baeten J.M. Jaoko W. McClelland R.S. Overbaugh J. Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. J. Virol. 2009 83 19 10269 10274 10.1128/JVI.01149‑09 19640996
    [Google Scholar]
  21. Gray E.S. Madiga M.C. Hermanus T. Moore P.L. Wibmer C.K. Tumba N.L. Werner L. Mlisana K. Sibeko S. Williamson C. Abdool Karim S.S. Morris L. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 2011 85 10 4828 4840 10.1128/JVI.00198‑11 21389135
    [Google Scholar]
  22. Schommers P. Kim D.S. Schlotz M. Kreer C. Eggeling R. Hake A. Stecher M. Park J. Radford C.E. Dingens A.S. Ercanoglu M.S. Gruell H. Odidika S. Dahlhaus M. Gieselmann L. Ahmadov E. Lawong R.Y. Heger E. Knops E. Wyen C. Kümmerle T. Römer K. Scholten S. Wolf T. Stephan C. Suárez I. Raju N. Adhikari A. Esser S. Streeck H. Duerr R. Nanfack A.J. Zolla-Pazner S. Geldmacher C. Geisenberger O. Kroidl A. William W. Maganga L. Ntinginya N.E. Georgiev I.S. Vehreschild J.J. Hoelscher M. Fätkenheuer G. Lavinder J.J. Bloom J.D. Seaman M.S. Lehmann C. Pfeifer N. Georgiou G. Klein F. Dynamics and durability of HIV-1 neutralization are determined by viral replication. Nat. Med. 2023 29 11 2763 2774 10.1038/s41591‑023‑02582‑3 37957379
    [Google Scholar]
  23. Buchacher A. Predl R. Strutzenberger K. Steinfellner W. Trkola A. Purtscher M. Gruber G. Tauer C. Steindl F. Jungbauer A. Katinger H. Generation of human monoclonal antibodies against HIV-1 proteins; Electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 1994 10 4 359 369 10.1089/aid.1994.10.359 7520721
    [Google Scholar]
  24. Burton D.R. Pyati J. Koduri R. Sharp S.J. Thornton G.B. Parren P.W.H.I. Sawyer L.S.W. Hendry R.M. Dunlop N. Nara P.L. Lamacchia M. Garratty E. Stiehm E.R. Bryson Y.J. Cao Y. Moore J.P. Ho D.D. Barbas C.F. III Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994 266 5187 1024 1027 10.1126/science.7973652 7973652
    [Google Scholar]
  25. Muster T. Steindl F. Purtscher M. Trkola A. Klima A. Himmler G. Rüker F. Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993 67 11 6642 6647 10.1128/jvi.67.11.6642‑6647.1993 7692082
    [Google Scholar]
  26. Trkola A. Purtscher M. Muster T. Ballaun C. Buchacher A. Sullivan N. Srinivasan K. Sodroski J. Moore J.P. Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996 70 2 1100 1108 10.1128/jvi.70.2.1100‑1108.1996 8551569
    [Google Scholar]
  27. Huang J. Ofek G. Laub L. Louder M.K. Doria-Rose N.A. Longo N.S. Imamichi H. Bailer R.T. Chakrabarti B. Sharma S.K. Alam S.M. Wang T. Yang Y. Zhang B. Migueles S.A. Wyatt R. Haynes B.F. Kwong P.D. Mascola J.R. Connors M. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012 491 7424 406 412 10.1038/nature11544 23151583
    [Google Scholar]
  28. Li M. Gao F. Mascola J.R. Stamatatos L. Polonis V.R. Koutsoukos M. Voss G. Goepfert P. Gilbert P. Greene K.M. Bilska M. Kothe D.L. Salazar-Gonzalez J.F. Wei X. Decker J.M. Hahn B.H. Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005 79 16 10108 10125 10.1128/JVI.79.16.10108‑10125.2005 16051804
    [Google Scholar]
  29. LaBranche C.C. McGuire A.T. Gray M.D. Behrens S. Zhou T. Sattentau Q.J. Peacock J. Eaton A. Greene K. Gao H. Tang H. Perez L.G. Saunders K.O. Mascola J.R. Haynes B.F. Stamatatos L. Montefiori D.C. Mascola J.R. Haynes B.F. Stamatatos L. Montefiori D.C. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. PLoS Pathog. 2018 14 11 e1007431 10.1371/journal.ppat.1007431 30395637
    [Google Scholar]
  30. Baba T.W. Liska V. Hofmann-Lehmann R. Vlasak J. Xu W. Ayehunie S. Cavacini L.A. Posner M.R. Katinger H. Stiegler G. Bernacky B.J. Rizvi T.A. Schmidt R. Hill L.R. Keeling M.E. Lu Y. Wright J.E. Chou T.C. Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection. Nat. Med. 2000 6 2 200 206 10.1038/72309 10655110
    [Google Scholar]
  31. Emini E.A. Schleif W.A. Nunberg J.H. Conley A.J. Eda Y. Tokiyoshi S. Putney S.D. Matsushrta S. Cobb K.E. Jett C.M. Eichberg J.W. Murthy K.K. Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody. Nature 1992 355 6362 728 730 10.1038/355728a0 1741059
    [Google Scholar]
  32. Mascola J.R. Lewis M.G. Stiegler G. Harris D. VanCott T.C. Hayes D. Louder M.K. Brown C.R. Sapan C.V. Frankel S.S. Lu Y. Robb M.L. Katinger H. Birx D.L. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999 73 5 4009 4018 10.1128/JVI.73.5.4009‑4018.1999 10196297
    [Google Scholar]
  33. Mascola J.R. Stiegler G. VanCott T.C. Katinger H. Carpenter C.B. Hanson C.E. Beary H. Hayes D. Frankel S.S. Birx D.L. Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 2000 6 2 207 210 10.1038/72318 10655111
    [Google Scholar]
  34. Moldt B. Rakasz E.G. Schultz N. Chan-Hui P.Y. Swiderek K. Weisgrau K.L. Piaskowski S.M. Bergman Z. Watkins D.I. Poignard P. Burton D.R. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 2012 109 46 18921 18925 10.1073/pnas.1214785109 23100539
    [Google Scholar]
  35. Shibata R. Igarashi T. Haigwood N. Buckler-White A. Ogert R. Ross W. Willey R. Cho M.W. Martin M.A. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 1999 5 2 204 210 10.1038/5568 9930869
    [Google Scholar]
  36. Shingai M. Donau O.K. Plishka R.J. Buckler-White A. Mascola J.R. Nabel G.J. Nason M.C. Montefiori D. Moldt B. Poignard P. Diskin R. Bjorkman P.J. Eckhaus M.A. Klein F. Mouquet H. Cetrulo Lorenzi J.C. Gazumyan A. Burton D.R. Nussenzweig M.C. Martin M.A. Nishimura Y. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 2014 211 10 2061 2074 10.1084/jem.20132494 25155019
    [Google Scholar]
  37. Xu L. Pegu A. Rao E. Doria-Rose N. Beninga J. McKee K. Lord D.M. Wei R.R. Deng G. Louder M. Schmidt S.D. Mankoff Z. Wu L. Asokan M. Beil C. Lange C. Leuschner W.D. Kruip J. Sendak R. Do Kwon Y. Zhou T. Chen X. Bailer R.T. Wang K. Choe M. Tartaglia L.J. Barouch D.H. O’Dell S. Todd J.P. Burton D.R. Roederer M. Connors M. Koup R.A. Kwong P.D. Yang Z. Mascola J.R. Nabel G.J. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 2017 358 6359 85 90 10.1126/science.aan8630 28931639
    [Google Scholar]
  38. Hessell A.J. Poignard P. Hunter M. Hangartner L. Tehrani D.M. Bleeker W.K. Parren P.W.H.I. Marx P.A. Burton D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009 15 8 951 954 10.1038/nm.1974 19525965
    [Google Scholar]
  39. Hessell A.J. Rakasz E.G. Poignard P. Hangartner L. Landucci G. Forthal D.N. Koff W.C. Watkins D.I. Burton D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009 5 5 e1000433 10.1371/journal.ppat.1000433 19436712
    [Google Scholar]
  40. Hessell A.J. Rakasz E.G. Tehrani D.M. Huber M. Weisgrau K.L. Landucci G. Forthal D.N. Koff W.C. Poignard P. Watkins D.I. Burton D.R. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J. Virol. 2010 84 3 1302 1313 10.1128/JVI.01272‑09 19906907
    [Google Scholar]
  41. Liu J. Ghneim K. Sok D. Bosche W.J. Li Y. Chipriano E. Berkemeier B. Oswald K. Borducchi E. Cabral C. Peter L. Brinkman A. Shetty M. Jimenez J. Mondesir J. Lee B. Giglio P. Chandrashekar A. Abbink P. Colantonio A. Gittens C. Baker C. Wagner W. Lewis M.G. Li W. Sekaly R.P. Lifson J.D. Burton D.R. Barouch D.H. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 2016 353 6303 1045 1049 10.1126/science.aag0491 27540005
    [Google Scholar]
  42. Parren P.W.H.I. Marx P.A. Hessell A.J. Luckay A. Harouse J. Cheng-Mayer C. Moore J.P. Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 2001 75 17 8340 8347 10.1128/JVI.75.17.8340‑8347.2001 11483779
    [Google Scholar]
  43. Santra S. Tomaras G.D. Warrier R. Nicely N.I. Liao H.X. Pollara J. Liu P. Alam S.M. Zhang R. Cocklin S.L. Shen X. Duffy R. Xia S.M. Schutte R.J. Pemble C.W. IV Dennison S.M. Li H. Chao A. Vidnovic K. Evans A. Klein K. Kumar A. Robinson J. Landucci G. Forthal D.N. Montefiori D.C. Kaewkungwal J. Nitayaphan S. Pitisuttithum P. Rerks-Ngarm S. Robb M.L. Michael N.L. Kim J.H. Soderberg K.A. Giorgi E.E. Blair L. Korber B.T. Moog C. Shattock R.J. Letvin N.L. Schmitz J.E. Moody M.A. Gao F. Ferrari G. Shaw G.M. Haynes B.F. Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in rhesus macaques. PLoS Pathog. 2015 11 8 e1005042 10.1371/journal.ppat.1005042 26237403
    [Google Scholar]
  44. Ward R.H.R. Capon D.J. Jett C.M. Murthy K.K. Mordenti J. Lucas C. Frie S.W. Prince A.M. Green J.D. Eichberg J.W. Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin. Nature 1991 352 6334 434 436 10.1038/352434a0 1907354
    [Google Scholar]
  45. Gardner M.R. Kattenhorn L.M. Kondur H.R. von Schaewen M. Dorfman T. Chiang J.J. Haworth K.G. Decker J.M. Alpert M.D. Bailey C.C. Neale E.S. Jr Fellinger C.H. Joshi V.R. Fuchs S.P. Martinez-Navio J.M. Quinlan B.D. Yao A.Y. Mouquet H. Gorman J. Zhang B. Poignard P. Nussenzweig M.C. Burton D.R. Kwong P.D. Piatak M. Jr Lifson J.D. Gao G. Desrosiers R.C. Evans D.T. Hahn B.H. Ploss A. Cannon P.M. Seaman M.S. Farzan M. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 2015 519 7541 87 91 10.1038/nature14264 25707797
    [Google Scholar]
  46. Balazs A.B. Chen J. Hong C.M. Rao D.S. Yang L. Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012 481 7379 81 84 10.1038/nature10660 22139420
    [Google Scholar]
  47. Balazs A.B. Ouyang Y. Hong C.M. Chen J. Nguyen S.M. Rao D.S. An D.S. Baltimore D. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 2014 20 3 296 300 10.1038/nm.3471 24509526
    [Google Scholar]
  48. Corey L. Gilbert P.B. Juraska M. Montefiori D.C. Morris L. Karuna S.T. Edupuganti S. Mgodi N.M. deCamp A.C. Rudnicki E. Huang Y. Gonzales P. Cabello R. Orrell C. Lama J.R. Laher F. Lazarus E.M. Sanchez J. Frank I. Hinojosa J. Sobieszczyk M.E. Marshall K.E. Mukwekwerere P.G. Makhema J. Baden L.R. Mullins J.I. Williamson C. Hural J. McElrath M.J. Bentley C. Takuva S. Gomez Lorenzo M.M. Burns D.N. Espy N. Randhawa A.K. Kochar N. Piwowar-Manning E. Donnell D.J. Sista N. Andrew P. Kublin J.G. Gray G. Ledgerwood J.E. Mascola J.R. Cohen M.S. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 2021 384 11 1003 1014 10.1056/NEJMoa2031738 33730454
    [Google Scholar]
  49. Barnes C.O. Schoofs T. Gnanapragasam P.N.P. Golijanin J. Huey-Tubman K.E. Gruell H. Schommers P. Suh-Toma N. Lee Y.E. Cetrulo Lorenzi J.C. Piechocka-Trocha A. Scheid J.F. West A.P. Jr Walker B.D. Seaman M.S. Klein F. Nussenzweig M.C. Bjorkman P.J. A naturally arising broad and potent CD4-binding site antibody with low somatic mutation. Sci. Adv. 2022 8 32 eabp8155 10.1126/sciadv.abp8155 35960796
    [Google Scholar]
  50. Huang J. Kang B.H. Ishida E. Zhou T. Griesman T. Sheng Z. Wu F. Doria-Rose N.A. Zhang B. McKee K. O’Dell S. Chuang G.Y. Druz A. Georgiev I.S. Schramm C.A. Zheng A. Joyce M.G. Asokan M. Ransier A. Darko S. Migueles S.A. Bailer R.T. Louder M.K. Alam S.M. Parks R. Kelsoe G. Von Holle T. Haynes B.F. Douek D.C. Hirsch V. Seaman M.S. Shapiro L. Mascola J.R. Kwong P.D. Connors M. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 2016 45 5 1108 1121 10.1016/j.immuni.2016.10.027 27851912
    [Google Scholar]
  51. Sajadi MM Dashti A Rikhtegaran Tehrani Z Tolbert WD Seaman MS Ouyang X Gohain N Pazgier M Kim D Cavet G Identification of near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses Cell 2018 173 7 1783 1795.e14 10.1016/j.cell.2018.03.061
    [Google Scholar]
  52. Scheid J.F. Mouquet H. Ueberheide B. Diskin R. Klein F. Oliveira T.Y.K. Pietzsch J. Fenyo D. Abadir A. Velinzon K. Hurley A. Myung S. Boulad F. Poignard P. Burton D.R. Pereyra F. Ho D.D. Walker B.D. Seaman M.S. Bjorkman P.J. Chait B.T. Nussenzweig M.C. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011 333 6049 1633 1637 10.1126/science.1207227 21764753
    [Google Scholar]
  53. Wu X. Zhang Z. Schramm C.A. Joyce M.G. Do Kwon Y. Zhou T. Sheng Z. Zhang B. O’Dell S. McKee K. Georgiev I.S. Chuang G.Y. Longo N.S. Lynch R.M. Saunders K.O. Soto C. Srivatsan S. Yang Y. Bailer R.T. Louder M.K. Mullikin J.C. Connors M. Kwong P.D. Mascola J.R. Shapiro L. Benjamin B. Blakesley R. Bouffard G. Brooks S. Coleman H. Dekhtyar M. Gregory M. Guan X. Gupta J. Han J. Hargrove A. Ho S. Legaspi R. Maduro Q. Masiello C. Maskeri B. McDowell J. Montemayor C. Park M. Riebow N. Schandler K. Schmidt B. Sison C. Stantripop M. Thomas J. Thomas P. Vemulapalli M. Young A. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 2015 161 3 470 485 10.1016/j.cell.2015.03.004 25865483
    [Google Scholar]
  54. Wu X. Zhou T. Zhu J. Zhang B. Georgiev I. Wang C. Chen X. Longo N.S. Louder M. McKee K. O’Dell S. Perfetto S. Schmidt S.D. Shi W. Wu L. Yang Y. Yang Z.Y. Yang Z. Zhang Z. Bonsignori M. Crump J.A. Kapiga S.H. Sam N.E. Haynes B.F. Simek M. Burton D.R. Koff W.C. Doria-Rose N.A. Connors M. Mullikin J.C. Nabel G.J. Roederer M. Shapiro L. Kwong P.D. Mascola J.R. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011 333 6049 1593 1602 10.1126/science.1207532 21835983
    [Google Scholar]
  55. Zhou T. Zhu J. Wu X. Moquin S. Zhang B. Acharya P. Georgiev I.S. Altae-Tran H.R. Chuang G.Y. Joyce M.G. Do Kwon Y. Longo N.S. Louder M.K. Luongo T. McKee K. Schramm C.A. Skinner J. Yang Y. Yang Z. Zhang Z. Zheng A. Bonsignori M. Haynes B.F. Scheid J.F. Nussenzweig M.C. Simek M. Burton D.R. Koff W.C. Mullikin J.C. Connors M. Shapiro L. Nabel G.J. Mascola J.R. Kwong P.D. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013 39 2 245 258 10.1016/j.immuni.2013.04.012 23911655
    [Google Scholar]
  56. Zhou T. Lynch R.M. Chen L. Acharya P. Wu X. Doria-Rose N.A. Joyce M.G. Lingwood D. Soto C. Bailer R.T. Ernandes M.J. Kong R. Longo N.S. Louder M.K. McKee K. O’Dell S. Schmidt S.D. Tran L. Yang Z. Druz A. Luongo T.S. Moquin S. Srivatsan S. Yang Y. Zhang B. Zheng A. Pancera M. Kirys T. Georgiev I.S. Gindin T. Peng H.P. Yang A.S. Mullikin J.C. Gray M.D. Stamatatos L. Burton D.R. Koff W.C. Cohen M.S. Haynes B.F. Casazza J.P. Connors M. Corti D. Lanzavecchia A. Sattentau Q.J. Weiss R.A. West A.P. Jr Bjorkman P.J. Scheid J.F. Nussenzweig M.C. Shapiro L. Mascola J.R. Kwong P.D. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 2015 161 6 1280 1292 10.1016/j.cell.2015.05.007 26004070
    [Google Scholar]
  57. Gristick H.B. von Boehmer L. West A.P. Jr Schamber M. Gazumyan A. Golijanin J. Seaman M.S. Fätkenheuer G. Klein F. Nussenzweig M.C. Bjorkman P.J. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat. Struct. Mol. Biol. 2016 23 10 906 915 10.1038/nsmb.3291 27617431
    [Google Scholar]
  58. van Schooten J. Farokhi E. Schorcht A. van den Kerkhof T.L.G.M. Gao H. van der Woude P. Burger J.A. Meesters T.G.R. Bijl T. Ghalaiyini R. Turner H.L. Dorning J. van Schaik B.D.C. van Kampen A.H.C. Labranche C.C. Stanfield R.L. Sok D. Montefiori D.C. Burton D.R. Seaman M.S. Ozorowski G. Wilson I.A. Sanders R.W. Ward A.B. van Gils M.J. Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein. Nat. Commun. 2022 13 1 4515 10.1038/s41467‑022‑32208‑0 35922441
    [Google Scholar]
  59. Andrabi R. Voss J.E. Liang C.H. Briney B. McCoy L.E. Wu C.Y. Wong C.H. Poignard P. Burton D.R. Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity 2015 43 5 959 973 10.1016/j.immuni.2015.10.014 26588781
    [Google Scholar]
  60. Doria-Rose N.A. Schramm C.A. Gorman J. Moore P.L. Bhiman J.N. DeKosky B.J. Ernandes M.J. Georgiev I.S. Kim H.J. Pancera M. Staupe R.P. Altae-Tran H.R. Bailer R.T. Crooks E.T. Cupo A. Druz A. Garrett N.J. Hoi K.H. Kong R. Louder M.K. Longo N.S. McKee K. Nonyane M. O’Dell S. Roark R.S. Rudicell R.S. Schmidt S.D. Sheward D.J. Soto C. Wibmer C.K. Yang Y. Zhang Z. Mullikin J.C. Binley J.M. Sanders R.W. Wilson I.A. Moore J.P. Ward A.B. Georgiou G. Williamson C. Abdool Karim S.S. Morris L. Kwong P.D. Shapiro L. Mascola J.R. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014 509 7498 55 62 10.1038/nature13036 24590074
    [Google Scholar]
  61. Gorman J. Chuang G.Y. Lai Y.T. Shen C.H. Boyington J.C. Druz A. Geng H. Louder M.K. McKee K. Rawi R. Verardi R. Yang Y. Zhang B. Doria-Rose N.A. Lin B. Moore P.L. Morris L. Shapiro L. Mascola J.R. Kwong P.D. Structure of super-potent antibody CAP256-VRC26.25 in complex with HIV-1 envelope reveals a combined mode of trimer-apex recognition. Cell Rep. 2020 31 1 107488 10.1016/j.celrep.2020.03.052 32268107
    [Google Scholar]
  62. Gorman J. Soto C. Yang M.M. Davenport T.M. Guttman M. Bailer R.T. Chambers M. Chuang G.Y. DeKosky B.J. Doria-Rose N.A. Druz A. Ernandes M.J. Georgiev I.S. Jarosinski M.C. Joyce M.G. Lemmin T.M. Leung S. Louder M.K. McDaniel J.R. Narpala S. Pancera M. Stuckey J. Wu X. Yang Y. Zhang B. Zhou T. Program N.I.S.C.C.S. Mullikin J.C. Baxa U. Georgiou G. McDermott A.B. Bonsignori M. Haynes B.F. Moore P.L. Morris L. Lee K.K. Shapiro L. Mascola J.R. Kwong P.D. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat. Struct. Mol. Biol. 2016 23 1 81 90 10.1038/nsmb.3144 26689967
    [Google Scholar]
  63. Julien J.P. Lee J.H. Cupo A. Murin C.D. Derking R. Hoffenberg S. Caulfield M.J. King C.R. Marozsan A.J. Klasse P.J. Sanders R.W. Moore J.P. Wilson I.A. Ward A.B. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc. Natl. Acad. Sci. USA 2013 110 11 4351 4356 10.1073/pnas.1217537110 23426631
    [Google Scholar]
  64. Pejchal R. Walker L.M. Stanfield R.L. Phogat S.K. Koff W.C. Poignard P. Burton D.R. Wilson I.A. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. USA 2010 107 25 11483 11488 10.1073/pnas.1004600107 20534513
    [Google Scholar]
  65. Barnes C.O. Gristick H.B. Freund N.T. Escolano A. Lyubimov A.Y. Hartweger H. West A.P. Jr Cohen A.E. Nussenzweig M.C. Bjorkman P.J. Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. Nat. Commun. 2018 9 1 1251 10.1038/s41467‑018‑03632‑y 29593217
    [Google Scholar]
  66. Bonsignori M. Kreider E.F. Fera D. Meyerhoff R.R. Bradley T. Wiehe K. Alam S.M. Aussedat B. Walkowicz W.E. Hwang K.K. Saunders K.O. Zhang R. Gladden M.A. Monroe A. Kumar A. Xia S.M. Cooper M. Louder M.K. McKee K. Bailer R.T. Pier B.W. Jette C.A. Kelsoe G. Williams W.B. Morris L. Kappes J. Wagh K. Kamanga G. Cohen M.S. Hraber P.T. Montefiori D.C. Trama A. Liao H.X. Kepler T.B. Moody M.A. Gao F. Danishefsky S.J. Mascola J.R. Shaw G.M. Hahn B.H. Harrison S.C. Korber B.T. Haynes B.F. Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies. Sci. Transl. Med. 2017 9 381 eaai7514 10.1126/scitranslmed.aai7514 28298420
    [Google Scholar]
  67. Doores K.J. Kong L. Krumm S.A. Le K.M. Sok D. Laserson U. Garces F. Poignard P. Wilson I.A. Burton D.R. Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope. J. Virol. 2015 89 2 1105 1118 10.1128/JVI.02905‑14 25378488
    [Google Scholar]
  68. Julien J.P. Sok D. Khayat R. Lee J.H. Doores K.J. Walker L.M. Ramos A. Diwanji D.C. Pejchal R. Cupo A. Katpally U. Depetris R.S. Stanfield R.L. McBride R. Marozsan A.J. Paulson J.C. Sanders R.W. Moore J.P. Burton D.R. Poignard P. Ward A.B. Wilson I.A. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 2013 9 5 e1003342 10.1371/journal.ppat.1003342 23658524
    [Google Scholar]
  69. Mouquet H. Scharf L. Euler Z. Liu Y. Eden C. Scheid J.F. Halper-Stromberg A. Gnanapragasam P.N.P. Spencer D.I.R. Seaman M.S. Schuitemaker H. Feizi T. Nussenzweig M.C. Bjorkman P.J. Complex-type N -glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA 2012 109 47 E3268 E3277 10.1073/pnas.1217207109 23115339
    [Google Scholar]
  70. Pancera M. Yang Y. Louder M.K. Gorman J. Lu G. McLellan J.S. Stuckey J. Zhu J. Burton D.R. Koff W.C. Mascola J.R. Kwong P.D. N332-Directed broadly neutralizing antibodies use diverse modes of HIV-1 recognition: Inferences from heavy-light chain complementation of function. PLoS One 2013 8 2 e55701 10.1371/journal.pone.0055701 23431362
    [Google Scholar]
  71. Pejchal R. Doores K.J. Walker L.M. Khayat R. Huang P.S. Wang S.K. Stanfield R.L. Julien J.P. Ramos A. Crispin M. Depetris R. Katpally U. Marozsan A. Cupo A. Maloveste S. Liu Y. McBride R. Ito Y. Sanders R.W. Ogohara C. Paulson J.C. Feizi T. Scanlan C.N. Wong C.H. Moore J.P. Olson W.C. Ward A.B. Poignard P. Schief W.R. Burton D.R. Wilson I.A. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011 334 6059 1097 1103 10.1126/science.1213256 21998254
    [Google Scholar]
  72. Calarese D.A. Scanlan C.N. Zwick M.B. Deechongkit S. Mimura Y. Kunert R. Zhu P. Wormald M.R. Stanfield R.L. Roux K.H. Kelly J.W. Rudd P.M. Dwek R.A. Katinger H. Burton D.R. Wilson I.A. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003 300 5628 2065 2071 10.1126/science.1083182 12829775
    [Google Scholar]
  73. Sanders R.W. Venturi M. Schiffner L. Kalyanaraman R. Katinger H. Lloyd K.O. Kwong P.D. Moore J.P. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 2002 76 14 7293 7305 10.1128/JVI.76.14.7293‑7305.2002 12072528
    [Google Scholar]
  74. Scanlan C.N. Pantophlet R. Wormald M.R. Ollmann Saphire E. Stanfield R. Wilson I.A. Katinger H. Dwek R.A. Rudd P.M. Burton D.R. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J. Virol. 2002 76 14 7306 7321 10.1128/JVI.76.14.7306‑7321.2002 12072529
    [Google Scholar]
  75. Kong R. Xu K. Zhou T. Acharya P. Lemmin T. Liu K. Ozorowski G. Soto C. Taft J.D. Bailer R.T. Cale E.M. Chen L. Choi C.W. Chuang G.Y. Doria-Rose N.A. Druz A. Georgiev I.S. Gorman J. Huang J. Joyce M.G. Louder M.K. Ma X. McKee K. O’Dell S. Pancera M. Yang Y. Blanchard S.C. Mothes W. Burton D.R. Koff W.C. Connors M. Ward A.B. Kwong P.D. Mascola J.R. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 2016 352 6287 828 833 10.1126/science.aae0474 27174988
    [Google Scholar]
  76. Stiegler G. Kunert R. Purtscher M. Wolbank S. Voglauer R. Steindl F. Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 2001 17 18 1757 1765 10.1089/08892220152741450 11788027
    [Google Scholar]
  77. Choudhry V. Zhang M.Y. Sidorov I.A. Louis J.M. Harris I. Dimitrov A.S. Bouma P. Cham F. Choudhary A. Rybak S.M. Fouts T. Montefiori D.C. Broder C.C. Quinnan G.V. Jr Dimitrov D.S. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 2007 363 1 79 90 10.1016/j.virol.2007.01.015 17306322
    [Google Scholar]
  78. Blattner C. Lee J.H. Sliepen K. Derking R. Falkowska E. de la Peña A.T. Cupo A. Julien J.P. van Gils M. Lee P.S. Peng W. Paulson J.C. Poignard P. Burton D.R. Moore J.P. Sanders R.W. Wilson I.A. Ward A.B. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 2014 40 5 669 680 10.1016/j.immuni.2014.04.008 24768348
    [Google Scholar]
  79. Scharf L. Scheid J.F. Lee J.H. West A.P. Jr Chen C. Gao H. Gnanapragasam P.N.P. Mares R. Seaman M.S. Ward A.B. Nussenzweig M.C. Bjorkman P.J. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep. 2014 7 3 785 795 10.1016/j.celrep.2014.04.001 24767986
    [Google Scholar]
  80. Wu X. Yang Z.Y. Li Y. Hogerkorp C.M. Schief W.R. Seaman M.S. Zhou T. Schmidt S.D. Wu L. Xu L. Longo N.S. McKee K. O’Dell S. Louder M.K. Wycuff D.L. Feng Y. Nason M. Doria-Rose N. Connors M. Kwong P.D. Roederer M. Wyatt R.T. Nabel G.J. Mascola J.R. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010 329 5993 856 861 10.1126/science.1187659 20616233
    [Google Scholar]
  81. Zhou T. Georgiev I. Wu X. Yang Z.Y. Dai K. Finzi A. Do Kwon Y. Scheid J.F. Shi W. Xu L. Yang Y. Zhu J. Nussenzweig M.C. Sodroski J. Shapiro L. Nabel G.J. Mascola J.R. Kwong P.D. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010 329 5993 811 817 10.1126/science.1192819 20616231
    [Google Scholar]
  82. Scharf L. West A.P. Jr Gao H. Lee T. Scheid J.F. Nussenzweig M.C. Bjorkman P.J. Diskin R. Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. Proc. Natl. Acad. Sci. USA 2013 110 15 6049 6054 10.1073/pnas.1303682110 23524883
    [Google Scholar]
  83. Scharf L. West A.P. Jr Sievers S.A. Chen C. Jiang S. Gao H. Gray M.D. McGuire A.T. Scheid J.F. Nussenzweig M.C. Stamatatos L. Bjorkman P.J. Structural basis for germline antibody recognition of HIV-1 immunogens. eLife 2016 5 e13783 10.7554/eLife.13783 26997349
    [Google Scholar]
  84. Diskin R. Scheid J.F. Marcovecchio P.M. West A.P. Jr Klein F. Gao H. Gnanapragasam P.N.P. Abadir A. Seaman M.S. Nussenzweig M.C. Bjorkman P.J. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011 334 6060 1289 1293 10.1126/science.1213782 22033520
    [Google Scholar]
  85. Yacoob C. Pancera M. Vigdorovich V. Oliver B.G. Glenn J.A. Feng J. Sather D.N. McGuire A.T. Stamatatos L. Differences in allelic frequency and CDRH3 region limit the engagement of HIV Env immunogens by putative VRC01 neutralizing antibody precursors. Cell Rep. 2016 17 6 1560 1570 10.1016/j.celrep.2016.10.017 27806295
    [Google Scholar]
  86. Bonsignori M. Scott E. Wiehe K. Easterhoff D. Alam S.M. Hwang K.K. Cooper M. Xia S.M. Zhang R. Montefiori D.C. Henderson R. Nie X. Kelsoe G. Moody M.A. Chen X. Joyce M.G. Kwong P.D. Connors M. Mascola J.R. McGuire A.T. Stamatatos L. Medina-Ramírez M. Sanders R.W. Saunders K.O. Kepler T.B. Haynes B.F. Inference of the HIV-1 VRC01 antibody lineage unmutated common ancestor reveals alternative pathways to overcome a key Glycan barrier. Immunity 2018 49 6 1162 1174.e8 10.1016/j.immuni.2018.10.015 30552024
    [Google Scholar]
  87. Gray M.D. Feng J. Weidle C.E. Cohen K.W. Ballweber-Fleming L. MacCamy A.J. Huynh C.N. Trichka J.J. Montefiori D. Ferrari G. Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain. bioRxiv 2021 2021.2008.2021.457217
    [Google Scholar]
  88. Hoot S. McGuire A.T. Cohen K.W. Strong R.K. Hangartner L. Klein F. Diskin R. Scheid J.F. Sather D.N. Burton D.R. Stamatatos L. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog. 2013 9 1 e1003106 10.1371/journal.ppat.1003106 23300456
    [Google Scholar]
  89. Jardine J. Julien J.P. Menis S. Ota T. Kalyuzhniy O. McGuire A. Sok D. Huang P.S. MacPherson S. Jones M. Nieusma T. Mathison J. Baker D. Ward A.B. Burton D.R. Stamatatos L. Nemazee D. Wilson I.A. Schief W.R. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013 340 6133 711 716 10.1126/science.1234150 23539181
    [Google Scholar]
  90. McGuire A.T. Dreyer A.M. Carbonetti S. Lippy A. Glenn J. Scheid J.F. Mouquet H. Stamatatos L. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science 2014 346 6215 1380 1383 10.1126/science.1259206 25504724
    [Google Scholar]
  91. McGuire A.T. Gray M.D. Dosenovic P. Gitlin A.D. Freund N.T. Petersen J. Correnti C. Johnsen W. Kegel R. Stuart A.B. Glenn J. Seaman M.S. Schief W.R. Strong R.K. Nussenzweig M.C. Stamatatos L. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice. Nat. Commun. 2016 7 1 10618 10.1038/ncomms10618 26907590
    [Google Scholar]
  92. Xiao X. Chen W. Feng Y. Zhu Z. Prabakaran P. Wang Y. Zhang M.Y. Longo N.S. Dimitrov D.S. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 2009 390 3 404 409 10.1016/j.bbrc.2009.09.029 19748484
    [Google Scholar]
  93. Dimitrov D.S. Therapeutic antibodies, vaccines and antibodyomes. MAbs 2010 2 3 347 356 10.4161/mabs.2.3.11779 20400863
    [Google Scholar]
  94. McGuire A.T. Hoot S. Dreyer A.M. Lippy A. Stuart A. Cohen K.W. Jardine J. Menis S. Scheid J.F. West A.P. Schief W.R. Stamatatos L. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 2013 210 4 655 663 10.1084/jem.20122824 23530120
    [Google Scholar]
  95. Cao J. Sullivan N. Desjardin E. Parolin C. Robinson J. Wyatt R. Sodroski J. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J. Virol. 1997 71 12 9808 9812 10.1128/jvi.71.12.9808‑9812.1997 9371651
    [Google Scholar]
  96. Stamatatos L. Cheng-Mayer C. An envelope modification that renders a primary, neutralization resistant, clade B HIV-1 isolate highly susceptible to neutralization by sera from other clades. J. Virol. 1998 72 7840 7845 10.1128/JVI.72.10.7840‑7845.1998 9733820
    [Google Scholar]
  97. Leggat D.J. Cohen K.W. Willis J.R. Fulp W.J. deCamp A.C. Kalyuzhniy O. Cottrell C.A. Menis S. Finak G. Ballweber-Fleming L. Srikanth A. Plyler J.R. Schiffner T. Liguori A. Rahaman F. Lombardo A. Philiponis V. Whaley R.E. Seese A. Brand J. Ruppel A.M. Hoyland W. Yates N.L. Williams L.D. Greene K. Gao H. Mahoney C.R. Corcoran M.M. Cagigi A. Taylor A. Brown D.M. Ambrozak D.R. Sincomb T. Hu X. Tingle R. Georgeson E. Eskandarzadeh S. Alavi N. Lu D. Mullen T.M. Kubitz M. Groschel B. Maenza J. Kolokythas O. Khati N. Bethony J. Crotty S. Roederer M. Karlsson Hedestam G.B. Tomaras G.D. Montefiori D. Diemert D. Koup R.A. Laufer D.S. McElrath M.J. McDermott A.B. Schief W.R. Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 2022 378 6623 eadd6502 10.1126/science.add6502 36454825
    [Google Scholar]
  98. Medina-Ramírez M. Garces F. Escolano A. Skog P. de Taeye S.W. Del Moral-Sanchez I. McGuire A.T. Yasmeen A. Behrens A.J. Ozorowski G. van den Kerkhof T.L.G.M. Freund N.T. Dosenovic P. Hua Y. Gitlin A.D. Cupo A. van der Woude P. Golabek M. Sliepen K. Blane T. Kootstra N. van Breemen M.J. Pritchard L.K. Stanfield R.L. Crispin M. Ward A.B. Stamatatos L. Klasse P.J. Moore J.P. Nemazee D. Nussenzweig M.C. Wilson I.A. Sanders R.W. Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. J. Exp. Med. 2017 214 9 2573 2590 10.1084/jem.20161160 28847869
    [Google Scholar]
  99. Jardine J.G. Kulp D.W. Havenar-Daughton C. Sarkar A. Briney B. Sok D. Sesterhenn F. Ereño-Orbea J. Kalyuzhniy O. Deresa I. Hu X. Spencer S. Jones M. Georgeson E. Adachi Y. Kubitz M. deCamp A.C. Julien J.P. Wilson I.A. Burton D.R. Crotty S. Schief W.R. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 2016 351 6280 1458 1463 10.1126/science.aad9195 27013733
    [Google Scholar]
  100. Hofmeyer T. Schmelz S. Degiacomi M.T. Dal Peraro M. Daneschdar M. Scrima A. van den Heuvel J. Heinz D.W. Kolmar H. Arranged sevenfold: Structural insights into the C-terminal oligomerization domain of human C4b-binding protein. J. Mol. Biol. 2013 425 8 1302 1317 10.1016/j.jmb.2012.12.017 23274142
    [Google Scholar]
  101. Dosenovic P. von Boehmer L. Escolano A. Jardine J. Freund N.T. Gitlin A.D. McGuire A.T. Kulp D.W. Oliveira T. Scharf L. Pietzsch J. Gray M.D. Cupo A. van Gils M.J. Yao K.H. Liu C. Gazumyan A. Seaman M.S. Björkman P.J. Sanders R.W. Moore J.P. Stamatatos L. Schief W.R. Nussenzweig M.C. Immunization for HIV-1 broadly neutralizing antibodies in human Ig Knockin mice. Cell 2015 161 7 1505 1515 10.1016/j.cell.2015.06.003 26091035
    [Google Scholar]
  102. Tian M. Cheng C. Chen X. Duan H. Cheng H.L. Dao M. Sheng Z. Kimble M. Wang L. Lin S. Schmidt S.D. Du Z. Joyce M.G. Chen Y. DeKosky B.J. Chen Y. Normandin E. Cantor E. Chen R.E. Doria-Rose N.A. Zhang Y. Shi W. Kong W.P. Choe M. Henry A.R. Laboune F. Georgiev I.S. Huang P.Y. Jain S. McGuire A.T. Georgeson E. Menis S. Douek D.C. Schief W.R. Stamatatos L. Kwong P.D. Shapiro L. Haynes B.F. Mascola J.R. Alt F.W. Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. Cell 2016 166 6 1471 1484.e18 10.1016/j.cell.2016.07.029 27610571
    [Google Scholar]
  103. West A.P. Jr Diskin R. Nussenzweig M.C. Bjorkman P.J. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc. Natl. Acad. Sci. USA 2012 109 30 E2083 E2090 10.1073/pnas.1208984109 22745174
    [Google Scholar]
  104. Briney B. Sok D. Jardine J.G. Kulp D.W. Skog P. Menis S. Jacak R. Kalyuzhniy O. de Val N. Sesterhenn F. Le K.M. Ramos A. Jones M. Saye-Francisco K.L. Blane T.R. Spencer S. Georgeson E. Hu X. Ozorowski G. Adachi Y. Kubitz M. Sarkar A. Wilson I.A. Ward A.B. Nemazee D. Burton D.R. Schief W.R. Tailored immunogens direct affinity maturation toward HIV neutralizing antibodies. Cell 2016 166 6 1459 1470.e11 10.1016/j.cell.2016.08.005 27610570
    [Google Scholar]
  105. Caniels T.G. Medina-Ramírez M. Zhang J. Sarkar A. Kumar S. LaBranche A. Derking R. Allen J.D. Snitselaar J.L. Capella-Pujol J. Sánchez I.M. Yasmeen A. Diaz M. Aldon Y. Bijl T.P.L. Venkatayogi S. Martin Beem J.S. Newman A. Jiang C. Lee W.H. Pater M. Burger J.A. van Breemen M.J. de Taeye S.W. Rantalainen K. LaBranche C. Saunders K.O. Montefiori D. Ozorowski G. Ward A.B. Crispin M. Moore J.P. Klasse P.J. Haynes B.F. Wilson I.A. Wiehe K. Verkoczy L. Sanders R.W. Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions. Cell Rep. Med. 2023 4 4 101003 10.1016/j.xcrm.2023.101003 37044090
    [Google Scholar]
  106. Chen X. Zhou T. Schmidt S.D. Duan H. Cheng C. Chuang G.Y. Gu Y. Louder M.K. Lin B.C. Shen C.H. Sheng Z. Zheng M.X. Doria-Rose N.A. Joyce M.G. Shapiro L. Tian M. Alt F.W. Kwong P.D. Mascola J.R. Vaccination induces maturation in a mouse model of diverse unmutated VRC01-class precursors to HIV-neutralizing antibodies with >50% breadth. Immunity 2021 54 2 324 339.e8 10.1016/j.immuni.2020.12.014 33453152
    [Google Scholar]
  107. Jardine J.G. Ota T. Sok D. Pauthner M. Kulp D.W. Kalyuzhniy O. Skog P.D. Thinnes T.C. Bhullar D. Briney B. Menis S. Jones M. Kubitz M. Spencer S. Adachi Y. Burton D.R. Schief W.R. Nemazee D. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 2015 349 6244 156 161 10.1126/science.aac5894 26089355
    [Google Scholar]
  108. Lin Y.R. Parks K.R. Weidle C. Naidu A.S. Khechaduri A. Riker A.O. Takushi B. Chun J.H. Borst A.J. Veesler D. Stuart A. Agrawal P. Gray M. Pancera M. Huang P.S. Stamatatos L. HIV-1 VRC01 germline-targeting immunogens select distinct epitope-specific B cell receptors. Immunity 2020 53 4 840 851.e6 10.1016/j.immuni.2020.09.007 33053332
    [Google Scholar]
  109. Parks K.R. MacCamy A.J. Trichka J. Gray M. Weidle C. Borst A.J. Khechaduri A. Takushi B. Agrawal P. Guenaga J. Wyatt R.T. Coler R. Seaman M. LaBranche C. Montefiori D.C. Veesler D. Pancera M. McGuire A. Stamatatos L. Overcoming steric restrictions of VRC01 HIV-1 neutralizing antibodies through immunization. Cell Rep. 2019 29 10 3060 3072.e7 10.1016/j.celrep.2019.10.071 31801073
    [Google Scholar]
  110. Knudsen M.L. Agrawal P. MacCamy A. Parks K.R. Gray M.D. Takushi B.N. Khechaduri A. Salladay K.R. Coler R.N. LaBranche C.C. Montefiori D. Stamatatos L. Adjuvants influence the maturation of VRC01-like antibodies during immunization. iScience 2022 25 11 105473 10.1016/j.isci.2022.105473 36405776
    [Google Scholar]
  111. Luo S. Jing C. Ye A.Y. Kratochvil S. Cottrell C.A. Koo J.H. Chapdelaine Williams A. Francisco L.V. Batra H. Lamperti E. Kalyuzhniy O. Zhang Y. Barbieri A. Manis J.P. Haynes B.F. Schief W.R. Batista F.D. Tian M. Alt F.W. Humanized V(D)J-rearranging and TdT-expressing mouse vaccine models with physiological HIV-1 broadly neutralizing antibody precursors. Proc. Natl. Acad. Sci. USA 2023 120 1 e2217883120 10.1073/pnas.2217883120 36574685
    [Google Scholar]
  112. Abbott R.K. Lee J.H. Menis S. Skog P. Rossi M. Ota T. Kulp D.W. Bhullar D. Kalyuzhniy O. Havenar-Daughton C. Schief W.R. Nemazee D. Crotty S. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity 2018 48 1 133 146.e6 10.1016/j.immuni.2017.11.023 29287996
    [Google Scholar]
  113. DeKosky B.J. Lungu O.I. Park D. Johnson E.L. Charab W. Chrysostomou C. Kuroda D. Ellington A.D. Ippolito G.C. Gray J.J. Georgiou G. Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires. Proc. Natl. Acad. Sci. USA 2016 113 19 E2636 E2645 10.1073/pnas.1525510113 27114511
    [Google Scholar]
  114. Havenar-Daughton C. Sarkar A. Kulp D.W. Toy L. Hu X. Deresa I. Kalyuzhniy O. Kaushik K. Upadhyay A.A. Menis S. Landais E. Cao L. Diedrich J.K. Kumar S. Schiffner T. Reiss S.M. Seumois G. Yates J.R. Paulson J.C. Bosinger S.E. Wilson I.A. Schief W.R. Crotty S. The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen. Sci. Transl. Med. 2018 10 448 eaat0381 10.1126/scitranslmed.aat0381 29973404
    [Google Scholar]
  115. Huang D. Abbott R.K. Havenar-Daughton C. Skog P.D. Al-Kolla R. Groschel B. Blane T.R. Menis S. Tran J.T. Thinnes T.C. Volpi S.A. Liguori A. Schiffner T. Villegas S.M. Kalyuzhniy O. Pintea M. Voss J.E. Phelps N. Tingle R. Rodriguez A.R. Martin G. Kupryianov S. deCamp A. Schief W.R. Nemazee D. Crotty S. B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Proc. Natl. Acad. Sci. USA 2020 117 37 22920 22931 10.1073/pnas.2004489117 32873644
    [Google Scholar]
  116. Kato Y. Abbott R.K. Freeman B.L. Haupt S. Groschel B. Silva M. Menis S. Irvine D.J. Schief W.R. Crotty S. Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. Immunity 2020 53 3 548 563.e8 10.1016/j.immuni.2020.08.001 32857950
    [Google Scholar]
  117. Dosenovic P. Kara E.E. Pettersson A.K. McGuire A.T. Gray M. Hartweger H. Thientosapol E.S. Stamatatos L. Nussenzweig M.C. Anti–HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. Proc. Natl. Acad. Sci. USA 2018 115 18 4743 4748 10.1073/pnas.1803457115 29666227
    [Google Scholar]
  118. Wang X. Cottrell C.A. Hu X. Ray R. Bottermann M. Villavicencio P.M. Yan Y. Xie Z. Warner J.E. Ellis-Pugh J.R. Kalyuzhniy O. Liguori A. Willis J.R. Menis S. Rämisch S. Eskandarzadeh S. Kubitz M. Tingle R. Phelps N. Groschel B. Himansu S. Carfi A. Kirsch K.H. Weldon S.R. Nair U. Schief W.R. Batista F.D. mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models. Sci. Immunol. 2024 9 95 eadn0622 10.1126/sciimmunol.adn0622 38753808
    [Google Scholar]
  119. Stamatatos L. ‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’. Curr. Opin. HIV AIDS 2023 18 6 309 314 10.1097/COH.0000000000000817 37712859
    [Google Scholar]
  120. Klein F. Diskin R. Scheid J.F. Gaebler C. Mouquet H. Georgiev I.S. Pancera M. Zhou T. Incesu R.B. Fu B.Z. Gnanapragasam P.N.P. Oliveira T.Y. Seaman M.S. Kwong P.D. Bjorkman P.J. Nussenzweig M.C. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 2013 153 1 126 138 10.1016/j.cell.2013.03.018 23540694
    [Google Scholar]
  121. Jardine J.G. Sok D. Julien J.P. Briney B. Sarkar A. Liang C.H. Scherer E.A. Henry Dunand C.J. Adachi Y. Diwanji D. Hsueh J. Jones M. Kalyuzhniy O. Kubitz M. Spencer S. Pauthner M. Saye-Francisco K.L. Sesterhenn F. Wilson P.C. Galloway D.M. Stanfield R.L. Wilson I.A. Burton D.R. Schief W.R. Minimally mutated HIV-1 broadly neutralizing antibodies to guide reductionist vaccine design. PLoS Pathog. 2016 12 8 e1005815 10.1371/journal.ppat.1005815 27560183
    [Google Scholar]
  122. Victora G.D. Nussenzweig M.C. Germinal centers. Annu. Rev. Immunol. 2012 30 1 429 457 10.1146/annurev‑immunol‑020711‑075032 22224772
    [Google Scholar]
  123. Cottrell C.A. Hu X. Lee J.H. Skog P. Luo S. Flynn C.T. McKenney K.R. Hurtado J. Kalyuzhniy O. Liguori A. Willis J.R. Landais E. Raemisch S. Chen X. Baboo S. Himansu S. Diedrich J.K. Duan H. Cheng C. Schiffner T. Bader D.L.V. Kulp D.W. Tingle R. Georgeson E. Eskandarzadeh S. Alavi N. Lu D. Sincomb T. Kubitz M. Mullen T.M. Yates J.R. III Paulson J.C. Mascola J.R. Alt F.W. Briney B. Sok D. Schief W.R. Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice. Sci. Transl. Med. 2024 16 748 eadn0223 10.1126/scitranslmed.adn0223 38753806
    [Google Scholar]
/content/journals/chr/10.2174/011570162X358302250206074255
Loading
The Germline Targeting Vaccine Concept: Overview and Updates from HIV Pre-Clinical and Clinical Trials
Bentham Science Publishers ; https://doi.org/10.2174/011570162X358302250206074255
/content/journals/chr/10.2174/011570162X358302250206074255
/content/journals/chr/10.2174/011570162X358302250206074255
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: VRC01-class ; Broadly neutralizing antibodies ; germline targeting ; 426c ; vaccines ; HIV

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test